Literature DB >> 2234731

The significance of moderate and severe inflammation on class I Papanicolaou smear.

T B Lawley1, R B Lee, R Kapela.   

Abstract

The significance of a cytologic diagnosis of moderate and severe inflammation with a normal (class I) Papanicolaou smear has not been addressed. A retrospective review of 596 consecutive cervical smears performed over 13 months revealed 85 women who had a class I cytologic smear with moderate to severe inflammation. Seventy-eight patients had colposcopic examinations and were considered for this study. Fifty-nine (75.6%) had cervical punch biopsies and/or endocervical biopsies. Of the 78, 19 (24.4%) had cervical condylomata and nine (11.5%) had cervical intraepithelial neoplasia. We conclude that class I cytologic smears with moderate to severe inflammation may be associated with findings of condylomata and cervical dysplasia.

Entities:  

Mesh:

Year:  1990        PMID: 2234731

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Risk factors for and relationship between bacterial vaginosis and cervicitis in a high risk population for cervicitis in Southern Iran.

Authors:  H Keshavarz; S W Duffy; A Sadeghi-Hassanabadi; Z Zolghadr; B Oboodi
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  Effect of concurrent lower genital tract infections on cervical cancer screening.

Authors:  J R Schwebke; M E Zajackowski
Journal:  Genitourin Med       Date:  1997-10

3.  A study on cervical cancer screening in asymptomatic women using Papanicolaou smear in a tertiary care hospital in an urban area of Mumbai, India.

Authors:  Omna Shaki; Barun Kumar Chakrabarty; N Nagaraja
Journal:  J Family Med Prim Care       Date:  2018 Jul-Aug

4.  Cervical Cancer Care Continuum in South India: Evidence from a Community-based Screening Program.

Authors:  E Vidhubala; K Niraimathi; Hemant Deepak Shewade; Sankar Mahadevan
Journal:  J Epidemiol Glob Health       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.